RxDoctor Payments DataLook up a doctor →

Sunildat Maheshwari, MD

Family Medicine · Gilbert, AZNPI 1417153164

Payments from drug & device makers

$2,020,781in general payments, 2019–2025

Across 674 payments — averaging $2998.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.2M
  • Amgen$493K
  • AstraZeneca$256K
  • GSK$36K
  • Alnylam Pharmaceuticals Inc.$27K
  • Teva Pharmaceuticals USA, Inc.$14K
  • plus $7K from 52 others
$69,067in research payments, 2019–2025

Across 27 payments — averaging $2558.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$67K
  • GSK$2K

What the payments were for

  • Travel & lodging$13,92559%
  • Food & beverage$9,72441%
  • Education$780%
  • Entertainment$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly82$1,187,558
Amgen27$492,501
AstraZeneca50$256,387
GSK39$35,677
Alnylam Pharmaceuticals Inc.4$27,181
Teva Pharmaceuticals USA, Inc.65$14,479
AbbVie(2 entities)80$1,407
Novo Nordisk60$832
Lilly USA, LLC46$564
Pfizer32$514
Boehringer Ingelheim20$329
Merck17$271
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$206
Abbott10$200
Dexcom, Inc.9$191
Johnson & Johnson12$165
Novartis7$163
Mylan Specialty L.p.9$158
Madrigal Pharmaceuticals1$140
Corcept Therapeutics9$138
Mirati Therapeutics, Inc.1$122
Sanofi-aventis U.S. LLC8$118
Gilead4$83
Biohaven Pharmaceutical Holding Company Ltd.5$81
Astellas Pharma US Inc4$77
Eisai Inc.3$68
Viatris Specialty LLC4$65
Phathom Pharmaceuticals, Inc.3$64
Takeda Pharmaceuticals U.S.A., Inc.4$64
Intuitive Surgical1$62
Biohaven Pharmaceuticals, Inc.3$61
Lundbeck LLC3$59
Sumitomo Pharma America, Inc.2$55
Angiodynamics, Inc.1$53
Cleerly, Inc.1$50
Medtronic(2 entities)3$49
Radius Health, Inc.3$48
Intra-sana Laboratories2$42
Boston Scientific3$42
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$40
Arbor Pharmaceuticals, Inc.3$38
Vanda Pharmaceuticals Inc.2$37
Xeris Pharmaceuticals, Inc.2$31
Exact Sciences2$31
Biotronik NRO, Inc.1$28
Axsome Therapeutics, Inc.1$25
Currax Pharmaceuticals LLC1$25
Actelion Pharmaceuticals US, Inc.1$25
Otsuka America Pharmaceutical, Inc.1$25
Optos, Inc.1$20
Halozyme Inc1$20
Bayer1$20
Hologic Sales And Service, LLC1$16
Nestle Healthcare Nutrition Inc.1$16
Scilex Pharmaceuticals Inc.1$16
Amarin Pharma, Inc.1$15
Kestra Medical Technology Services, Inc.1$14
Azurity Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020,781 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$885,414
Medicare patients
1,293
Services billed
17,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$106,113
MounjaroTirzepatide71$78,070
JardianceEmpagliflozin33$53,432
EliquisApixaban38$47,354
XareltoRivaroxaban36$44,352
RybelsusSemaglutide16$38,944
TrulicityDulaglutide18$28,195
Synjardy XrEmpagliflozin/Metformin Hcl13$27,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,852
FarxigaDapagliflozin Propanediol15$21,759
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,854
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,487
Breo ElliptaFluticasone/Vilanterol16$9,448
Tresiba Flextouch U-100Insulin Degludec14$8,892
PaxlovidNirmatrelvir/Ritonavir31$7,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$832$145,05792 claims
Lilly USA, LLCMounjaro, Trulicity$564$106,26589 claims
Boehringer IngelheimJardiance, Synjardy Xr$329$80,67846 claims
PfizerEliquis, Paxlovid$514$54,49969 claims
Johnson & JohnsonXarelto$165$44,35236 claims
AstraZenecaFarxiga, Breztri Aerosphere$256,387$37,61339 claims
GSKTrelegy Ellipta, Breo Ellipta$35,677$33,30047 claims
AbbVieSynthroid$1,407$1,48930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →